53BP1 Supports Immunoglobulin Class Switch Recombination Independently of Its DNA Double-Strand Break End Protection Function

Authors
Devakumar Sundaravinayagam, Ali Rahjouei, Matteo Andreani, ..., Violeta Coralluzzo, Oliver Daumke, Michela Di Virgilio

Correspondence
michela.divirgilio@mdc-berlin.de

In Brief
Class switch recombination (CSR) occurs via non-homologous end joining (NHEJ) of programmed DNA double-strand breaks (DSBs) at the immunoglobulin heavy chain locus. Sundaravinayagam et al. show that inhibition of DSB resection does not correlate with CSR efficiency and that regulation of DSB processing plays a limited role during CSR.

Highlights
- 53BP1 oligomerization is largely dispensable for inhibition of DSB resection
- 53BP1 higher order oligomerization is a pre-requisite for CSR
- B lymphocytes devoid of 53BP1-Rif1 DSB end protection activity undergo robust CSR
- 53BP1-mediated DSB end mobility is dispensable for CSR
53BP1 Supports Immunoglobulin Class Switch Recombination Independently of Its DNA Double-Strand Break End Protection Function

Devakumar Sundaravinayagam, 1 Ali Rahjouei, 1 Matteo Andreani, 1 Dagnija Tupiña, 2 Sandhya Balasubramanian, 1 Tannishtha Saha, 1 Verónica Delgado-Benito, 1 Violeta Coralluzzo, 1 Oliver Daumke, 2 and Michela Di Virgilio 1,3,*

1Laboratory of DNA Repair and Maintenance of Genome Stability, Max Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany
2Laboratory of Structural Biology of Membrane-Associated Processes, Max Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany
3Lead Contact
*Correspondence: michela.divirgilio@mdc-berlin.de
https://doi.org/10.1016/j.celrep.2019.06.035

SUMMARY

Class switch recombination (CSR) is a DNA recombination reaction that diversifies the effector functions of antibodies. CSR occurs via the formation and non-homologous end joining (NHEJ) repair of programmed DNA double-strand breaks (DSBs) at the immunoglobulin heavy chain locus. The DNA repair factors 53BP1 and Rif1 promote NHEJ and CSR by protecting DSBs against resection. However, to what extent repression of DNA end resection contributes to CSR is unknown. Here, we show that B lymphocytes devoid of 53BP1-Rif1-dependent DSB end protection activity undergo robust CSR. Inactivation of specific sets of phospho-sites within 53BP1 N-terminal SQ/TQ motifs abrogates Rif1 recruitment and inhibition of resection but only mildly reduces CSR. Furthermore, mutations within 53BP1 oligomerization domain abolish CSR without substantially affecting DNA end processing. Thus, inhibition of DNA end resection does not correlate with CSR efficiency, indicating that regulation of DSB processing is not a key determinant step in CSR.

INTRODUCTION

The diversity of human immunoglobulin (Ig) gene repertoire is shaped by antibody diversification processes occurring at different stages of B lymphocytes development (Dudley et al., 2005; Methot and Di Noia, 2017). Class switch recombination (CSR) is a DNA rearrangement reaction occurring in mature B lymphocytes, which replaces the constant portion of the IgM heavy chain with one of the alternative isotypes (IgG, IgA, or IgE). As a consequence, this process alters the Ig effector function without affecting its antigen specificity (Chaudhuri and Alt, 2004; Methot and Di Noia, 2017). CSR is crucial to the establishment of a proper immune response because it enhances the capability of antigen-specific Igs to effectively dispose of the pathogens (Durandy et al., 2013).
Figure 1. Disruption of 53BP1 Higher Order Oligomerization Abrogates CSR without Affecting DSB End Protection

(A) Schematic representation of 53BP1 protein domains and OD mutants. LC8, LC8 (8 kDa light chain dynein)-binding motif; OD, oligomerization domain; Tudor, Tudor domain; UDR, ubiquitylation-dependent recruitment motif; ΔBRCT, BRCA1 C terminus domains-truncated.

(legend continued on next page)
2004), a DSB repair protein that has emerged as a key regulator of DNA end processing (Panier and Boulton, 2014; Zimmermann and de Lange, 2014). 53BP1 binds damaged chromatin and recruits its phospho-dependent interactor Rif1, which protects DSB ends against processing by the DNA resection-promoting factor CtIP (Chapman et al., 2013; Di Virgilio et al., 2013; Escriberno-Díaz et al., 2013; Feng et al., 2013; Zimmermann et al., 2013). This function is mediated by the downstream REV7-SHLD1-SHLD2-SHLD3 (shieldin) and CTC1-STN1-TEN1 (CST) complexes, which localize to sites of DNA damage and counteract DSB end resection (Dev et al., 2018; Findlay et al., 2018; Ghezraoui et al., 2018; Gupta et al., 2018; Mirman et al., 2018; Noordermeer et al., 2018; Tomida et al., 2018). In addition to CSR, the DNA end resection inhibitory function of 53BP1-Rif1-shieldin promotes fusion of telomeres that lack shelterin protection, and end joining of unrepaird chromatin breaks into radial chromosomes in Brca1-deficient cells (Bunting et al., 2010; Chapman et al., 2013; Dev et al., 2018; Dimitrova et al., 2008; Ghezraoui et al., 2018; Gupta et al., 2018; Mirman et al., 2018; Sfeir and de Lange, 2012; Zimmermann et al., 2013). These aberrant DNA repair reactions require 53BP1-dependent DSB end mobility in addition to its DNA end protection function (Dimitrova et al., 2008; Lotsberger et al., 2015).

Protection of AID-induced DSBs against resection is thought to play a central role during CSR. However, the actual extent to which 53BP1-Rif1-dependent repression of DNA resection is required for CSR is not known. Here, we dissected the contributed function of the different functions of 53BP1 to CSR. We show that CSR is only marginally dependent on 53BP1-Rif1-mediated inhibition of DNA end processing, whereas the formation of higher order 53BP1 oligomers is crucial for the reaction. Furthermore, CSR does not require the DSB-induced chromatin mobility function of 53BP1. This sets CSR apart from the other DNA repair reactions mediated by 53BP1, fusion of deprotected telomeres and formation of radial chromosomes.

**RESULTS**

**Disruption of 53BP1 Higher Order Oligomerization Abrogates CSR**

Deletion of amino acids 1231–1270 of human 53BP1 interferes with 53BP1 oligomerization and abrogates its ability to rescue CSR in 53BP1-deficient B lymphocytes (Bothmer et al., 2011; Ward et al., 2006; Zgheib et al., 2009). This amino acid stretch contains predicted secondary structure elements (Figures 1A and S1A), suggesting the presence of a folded oligomerization domain (OD) in this region. To dissect how 53BP1 multimerization supports CSR, we fused the peptide sequence encompassing amino acids 1233–1288 to the maltose-binding protein (MBP) (Figures S1B and S1C) and assessed the oligomerization status of the fusion protein by gel filtration analysis coupled to right-angle light scattering (RALS). In these experiments, MBP-OD eluted as a tetramer (Figure 1B; MBP-ODWT). Mutation of the evolutionarily conserved residue D1256 led to a dimeric species, whereas the deletion of the OD core (amino acids 1254–1258) rendered the protein monomeric (Figure 1B). In agreement with these data, co-immunoprecipitation analysis of differentially tagged 53BP1 constructs showed that deletion of the OD core destabilized 53BP1 oligomerization more severely than the D1256A mutation (Figure 1C). These findings indicate that the OD acts as an independent tetramerization module, and D1256 is part of an interface that mediates dimerization of 53BP1 dimers. Notably, this analysis provided us with a tool to dissect the role of 53BP1 dimerization and tetramerization for CSR and the regulation of DNA end resection.

To assess how the differential assembly of 53BP1 influenced its ability to support CSR, we compared the capability of 53BP1*ODwt*, 53BP1*ODcore*, and 53BP1*D1256A* to rescue CSR in 53bp1−/− B cells. We used primary cultures of splenocytes and monitored CSR ex vivo to IgG1 in response to stimulation with LPS and IL-4. As expected, 53bp1−/− B cells exhibited

![Graph showing quantification of the BrdU FACS data represented in (I) for four experiments performed on three independent sets of reconstituted cell lines. Numbers above each bar indicate the fold mean BrdU intensity over WT, which was set to 1.](image-url)

Significance in (D), (F), (G), and (J) was calculated using the Mann-Whitney U test, and error bars represent SD. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001; ns, not significant. See also Figure S3.
10-fold lower levels of CSR compared with wild-type (WT) cells, and reconstitution with 53BP1WT efficiently rescued CSR (Figures 1D and 1E). On the contrary, none of the OD mutants significantly elevated CSR efficiency above the levels of the empty vector (EV) control or of a 53BP1 mutant that cannot associate with chromatin (53BP1mTudor) (Figure 1D). We concluded that the integrity of 53BP1 higher order oligomers is a pre-requisite for CSR.

**Oligomerization-Impaired 53BP1 Is Able to Counteract DSB End Resection**

In undamaged cells, 53BP1 associates with its direct binding partner Tudor interacting repair regulator (TIRR), which binds to 53BP1 tandem Tudor domain and masks the H4K20me2 binding surface (Botuyan et al., 2018; Dai et al., 2018; Drané et al., 2017; Wang et al., 2018; Zhang et al., 2017). Upon DNA damage, the 53BP1-TIRR complex dissociates (Drané et al., 2017; Zhang et al., 2017), and 53BP1 is recruited to the damaged chromatin via the direct bivalent interaction of its Tudor domain and ubiquitination-dependent recruitment (UDR) motif with H4K20me2 and H2AK15ub histone modifications, respectively (Botuyan et al., 2006; Fradet-Turcotte et al., 2013; Huyen et al., 2004; Sanders et al., 2004). 53BP1 engages the modified nucleosomes as a dimer in a pincer-like binding mode, and this interaction arrangement has been postulated to enable its DNA end resection inhibitory activity (Fradet-Turcotte et al., 2013; Wilson et al., 2016).

To assess to what extent impaired oligomerization of 53BP1 affects DNA end protection against resection, we first examined the ability of 53BP1 OD mutants to recruit Rif1 to sites of ionizing radiation (IR)-induced DNA damage. To this end, we reconstituted 53bp1+/− immortalized mouse embryonic fibroblasts (iMEFs) with 53BP1WT and OD mutant constructs (Figure S2A) and monitored 53BP1 and Rif1 irradiation-induced foci (IRIF) formation by high-throughput microscopy quantification. As expected, the constitutive association of 53BP1 with chromatin (53BP1mTudor) and its DNA damage-induced recruitment (53BP1mLDRA) were necessary for efficient 53BP1 IRIF formation (Figures 1F and S2B). In contrast, mutations or deletions disrupting the OD assembly or deletion of the entire OD only partially affected 53BP1 localization to DSBs (Figures 1F and S2B). Furthermore, the OD mutants were either as proficient as 53BP1WT (53BP1D1256A), or only minimally affected (53BP1ΔIsog and 53BP1ΔCore) in recruiting Rif1 to damaged chromatin (Figures 1G and S2B). This indicates that the reduced capability of 53BP1 to localize to sites of DNA damage does not significantly interfere with its ability to recruit Rif1.

Next, we tested the capability of these mutants to repress resection of DNA breaks induced by the radiomimetic drug nocarzinostatin (NCS). To this end, we used the 5-bromo-2′-deoxyuridine (BrdU) DNA end resection assay, which measures the levels of BrdU exposed by DNA processing as a quantitative readout for DNA end resection (Figure 1H). In agreement with the well-established role of 53BP1 in the inhibition of DNA end resection, cells transfected with EV or the 53BP1mTudor mutant displayed a high BrdU signal (Figures 1I and 1J), which is indicative of extensive DNA processing. Reconstitution with 53BP1WT rescued the phenotype (Figures 1I and 1J). OD mutant-expressing iMEFs exhibited only slightly increased BrdU levels compared with 53BP1WT (Figures 1I and 1J), indicating that assembly via the OD does not have a major impact on 53BP1-mediated inhibition of DNA end processing.

To assess for DNA end resection at the single nucleotide level, we used CRISPR/Cas9 nuclease and AID as DNA break-inducing source in CH12 cells. CH12 is a murine B cell lymphoma line that expresses AID and undergoes efficient CSR to IgA following cytokine stimulation (Nakamura et al., 1996). We used CRISPR-Cas9 somatic gene targeting to generate a CH12 cell line that harbored a deletion in the 53bp1 locus encompassing the OD core (53bp1Δ6 CH12) (Figures S3A and S3B). This cell line recapitulated the severe CSR deficiency (Figure S3C) of oligomutant-reconstituted primary B cells (Figure 1D).

We first monitored processing of Cas9-induced breaks at the Rosa26 locus using a well-established DSB end resection assay (Rosa26-ERA; Figure S3D). 53bp1Δ6 CH12 cells were as proficient as WT cells in preventing resection of CRISPR-Cas9-induced DSBs (Figure S3D). Next, we compared the frequency and length of microhomoologies (MHs) at Sμ-Sx junctions in cells activated to undergo CSR. 53BP1 deficiency results in CSR junctions skewed toward the preferential use of MHs as a consequence of increased resection of AID-induced breaks (Panchakshari et al., 2018). In agreement with this observation, 53bp1−/− CH12 cells displayed the expected bias toward MH-dependent end joining, with twice as many junctions as in WT cells presenting ≥3 bp MH (Figure S3E; Table S1). In contrast, Sμ-Sx ligation events with ≥3 bp MH were only modestly increased in 53bp1−/− cells (Figure S3E; Table S1). In line with these results, 53bp1−/− CH12 cells accumulated reduced levels of the single-stranded binding protein complex RPA at donor and acceptor switch regions compared with 53bp1+/− CH12 (Figure S3F).

Altogether, these findings indicate that the assembly of 53BP1 higher order oligomers via the OD is largely dispensable for inhibition of DSB resection yet essential for CSR.

**DSB End Protection-Deficient B Lymphocytes Undergo Robust CSR**

Following the generation of AID-induced breaks, 53BP1 recruits Rif1 to protect switch region breaks against resection (Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Díaz et al., 2013). Given the severe defect of the OD core mutants to support CSR despite minimally affected DNA end protection capabilities, we next examined to what extent the regulation of DNA end resection contributed to 53BP1’s role in CSR.

53BP1’s ability to inhibit DNA end resection is dependent on phosphorylation of the N-terminal SQ/TQ sites, as a mutant bearing alanine substitutions of all 28 N-terminal motifs (53BP1A28A; Figure 2A) cannot interact with Rif1 and support CSR despite being normally recruited to sites of DNA damage (Bothmer et al., 2011; Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Díaz et al., 2013). However, 53BP1A28A is also impaired in DNA damage-induced chromatin mobility, a Rif1-independent function of 53BP1 that is required for both telomere fusion and radial formation (Dimitrova et al., 2008; Lottersberger et al., 2013; Zimmermann et al., 2013). To assess the specific contribution of Rif1-mediated inhibition of DSB resection to CSR, we generated 53BP1 mutants that harbored alanine substitutions in the SQ/TQ sites within the N-terminal DNA end
Figure 2. Inactivation of 53BP1 SQ/TQ Sites T302 to S625 Is Sufficient to Abolish Rif1-Dependent Inhibition of DNA End Resection

(A) Top: schematic representation of 53BP1 protein with the position of the 28 N-terminal SQ/TQ motifs indicated as black circles. Bottom: schematic representation of the 53BP1 phospho mutants with S/TQ sites indicated as black circles and S/TQ-to-AQ substitutions marked in light gray. Pro, DNA end protection SQ/TQ set; Mob, DNA mobility SQ/TQ set.

(B and C) Automated IRIF quantification of immunofluorescent staining for 53BP1 (B) and Rif1 (C) in irradiated (10 Gy; 2 h recovery time) 53bp1/C0/C0 iMEFs reconstituted with the indicated constructs. The top graph within each panel shows a representative experiment, and the bottom graph summarizes the mean values of three experiments performed on three independent sets of reconstituted cell lines. Each symbol in the top graph represents a single cell, and the number of scored cells was ≥200 per sample. The mean is indicated. See also Figure S2D for representative immunofluorescent staining images.

(D) Representative BrdU FACS plots showing levels of resection in NCS-treated 53bp1/C0/C0 iMEFs reconstituted with the indicated constructs.

(E) Summary graph showing quantification of the BrdU FACS data represented in (D) for six experiments performed on three independent sets of reconstituted cell lines. Numbers above each bar indicate the fold mean BrdU intensity over WT, which was set to 1. Significance in (B), (C), and (E) was calculated using the Mann-Whitney U test, and error bars represent SD. **p \leq 0.01 and ****p \leq 0.0001; ns, not significant. See also Figure S4B.
This yielded 53BP1<sup>Pro</sup>, which contained mutations in the first 15 N-terminal SQ/TQ sites, and 53BP1<sup>ΔRif1</sup>, which preserved the SQ sites in the PTP1-binding region (Figure 2A).

To assess whether abrogation of SQ/TQ phosphorylation in the 53BP1<sup>Pro</sup> and 53BP1<sup>ΔRif1</sup> mutants interfered with Rif1 interaction and recruitment to DSBs, we reconstituted 53bp1<sup>−/−</sup> iMEFs with 53BP1<sup>WT</sup> and 53BP1 phospho mutants (Figure S2C), and monitored 53BP1 and Rif1 foci formation after irradiation. In agreement with the observation that N-terminal phosphorylation is dispensable for recruitment of 53BP1 to sites of DNA damage, 53BP1<sup>28A</sup> (Bothmer et al., 2011), 53BP1<sup>ΔPro</sup> and 53BP1<sup>ΔRif1</sup> foci were readily detectable following irradiation (Figures 2B and S2D). However, Rif1 did not form IRIF in 53BP1<sup>Pro</sup> and 53BP1<sup>ΔRif1</sup>-reconstituted cells (Figures 2C and S2D), thus indicating that both phospho mutants cannot support Rif1 relocalization to DSBs.

We next tested whether the inability of 53BP1<sup>Pro</sup> and 53BP1<sup>ΔRif1</sup> to recruit Rif1 to sites of DNA damage translated into impaired DNA end resection inhibition. iMEFs reconstituted with Rif1 interaction-deficient 53BP1 mutants displayed the same increased levels of resection as cells lacking 53BP1 (EV transduced) or cells expressing a 53BP1 mutant defective in DSB-induced chromatin recruitment (53BP1<sup>μUDR</sup>) (Figures 2D and 2E). These experiments confirm that Rif1 is the major effector in the regulation of DNA end resection downstream 53BP1. Altogether, these results indicate that abrogation of phosphorylation at SQ/TQ sites T302 to S625 is sufficient to abolish Rif1 recruitment to DSBs and 53BP1-dependent DNA end protection.

To assess to what extent 53BP1-Rif1-mediated regulation of DNA end processing contributes to CSR, we reconstituted 53bp1<sup>−/−</sup> splenocytes with 53BP1<sup>Pro</sup> and 53BP1<sup>ΔRif1</sup> (Figures 3A–3C). Phosphomutant-expressing splenocyte cultures displayed the same proliferation capability as their WT counterpart (Figure S4A). We first assessed 53BP1<sup>ΔPro</sup> and 53BP1<sup>ΔRif1</sup> profi ciency to interact with Rif1 following DNA damage by co-immunoprecipitation analysis. In agreement with the inability to recruit Rif1 to IR-induced DSBs in MEFS (Figures 2C and S2D), 53BP1<sup>ΔPro</sup> and 53BP1<sup>ΔRif1</sup> failed to co-immunoprecipitate Rif1 following IR in B cells (Figure S4B). Next, we assessed CSR efficiency ex vivo in response to stimulation conditions that induce class switching to different isotypes. We monitored switching to IgG1, IgG2b, and IgG3 because CSR to these isotypes is robust, and thus it ensures a large dynamic range and a more accurate detection of even subtle differences in CSR levels. Whereas CSR was abrogated to all tested isotypes in 53bp1<sup>−/−</sup> B cells transduced with EV or 53BP1<sup>μUDR</sup>, Rif1 interaction-deficient 53BP1 rescued CSR to a considerable extent under all stimulation conditions (Figures 3D–3F; mean values of 72%, 66%, and 65% of WT levels for IgG1, IgG2b, and IgG3, respectively, for 53BP1<sup>ΔRif1</sup>). Taken together, these results indicate that 53BP1-Rif1 DSB end protection plays a limited role in 53BP1’s ability to support CSR.

**DISCUSSION**

Whereas CSR is predominantly dependent on NHEJ, the repetitive nature of the switch regions favors MMEJ-mediated intra-S recombination, and the ability of 53BP1-Rif1 to counteract DNA end processing is believed to contribute substantially to the severe CSR defects caused by deficiency in these DSB repair factors. Here, we showed that B lymphocytes devoid of 53BP1-Rif1-mediated DNA end protection can undergo robust class switching. Conversely, defects in higher order multimerization completely abolish 53BP1’s ability to support CSR without having a major impact on its DNA end resection inhibitory function. Considering the near complete abrogation of CSR in 53BP1- and Rif1-deficient B cells (Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Diaz et al., 2013; Manis et al., 2004; Ward et al., 2004), the major implication of these findings is that 53BP1 and Rif1 contribute multiple functions to CSR, with the regulation of DNA end resection activity only marginally influencing the process. This would explain the surprising observation that inhibition of CtIP-mediated end resection only negligibly rescues the CSR defect in 53BP1 and Rif1-deficient B lymphocytes (Bothmer et al., 2013; Di Virgilio et al., 2013).

Despite a partially defective association with damaged chromatin, 53BP1 OD mutants supported considerable Rif1 recruitment and inhibition of DNA end resection. These results are reminiscent of the behavior of OD-impaired 53BP1 at dysfunctional telomeres (Lottersberger et al., 2013). 53BP1<sup>ΔOligo</sup> exhibited only a mild localization defect to deprotected telomere-induced foci (TIFs) but was fully proficient with regard to counteracting CtIP-mediated telomere resection (Lottersberger et al., 2013). These observations raise the possibility that an...
independent oligomerization module may compensate for mutations within the OD and support sufficient levels of 53BP1 recruitment to damaged sites to ensure repression of DNA end processing (DSBs or dysfunctional telomeres). Indeed, during the preparation of this paper, another study reported that binding of the dimerization-inducing protein DYNLL1 to the LC8 motif in 53BP1 promoted OD-independent oligomerization and chromatin association (Becker et al., 2018). Given the milder chromatin recruitment defect of the 53BP1 LC8 mutant (Becker et al., 2018), the OD is likely to play a key role in the stabilization of 53BP1 oligomers.

We have found that the OD provides a tetramerization interface, and efficient higher order 53BP1 multimerization is essential for CSR. A single mutation within the OD core that still

Figure 3. DSB End Protection-Deficient B Lymphocytes Undergo Robust CSR
(A–C) Representative WB analysis of 53bp1<sup>−/−</sup> B lymphocytes reconstituted with the indicated 53BP1 viral constructs and stimulated to induce CSR to IgG1 (A), IgG2b (B), or IgG3 (C). Asterisk indicates an aspecific band used for internal normalization of protein levels. Numbers underneath each lane indicate mean values from relative quantification of 53BP1 WT and mutant protein levels in reconstituted 53bp1<sup>−/−</sup> splenocytes cultures compared with endogenous protein in the WT B cell culture. Quantification summarizes WB analyses of three independently reconstituted cultures per stimulation condition.

(D–F) Top: representative flow cytometry plots measuring CSR to IgG1 (D), IgG2b (E), and IgG3 (F) in primary cultures of 53BP1 construct-reconstituted 53bp1<sup>−/−</sup> B lymphocytes. Bottom: summary dot plot for three independent experiments. CSR efficiencies within each experiment were normalized to the CSR value of 53BP1<sup>WT</sup>-reconstituted cells, which was set to 100%. Significance was calculated using the Mann-Whitney U test, and error bars represent SD. *p ≤ 0.05 and **p ≤ 0.01.
supports dimerization of the OD module abolishes CSR. Interestingly, deletion of the OD had a minor effect on the end joining of deprotected telomeric ends that specifically concerned the longest multichromosome fusion events, which might be limited by a less efficient interaction of distally located telomeric ends (Lottersberger et al., 2013). These findings are in agreement with a model in which 53BP1 dimers represent the minimum nucleosome-binding unit to allow DNA damage-dependent recruitment and inhibition of DNA end resection, whereas tetramerization (and higher order assembly) provides a tethering activity to bridge and stabilize distally located DNA ends (Figure 4C), including AID-induced DSBs in donor and acceptor switch regions or spatially separated telomeric ends. Consistent with this idea, 53BP1 facilitates long-range DNA end joining during V(D)J recombination (Difilippantonio et al., 2008). The combined contribution of DSB end protection and distal break tethering to CSR explains the increase in MMEJ-mediated intra-S region repair events in 53BP1-deficient B cells (Reina-San-Martin et al., 2007).

CSR is a complex process that relies on the coordinated interplay of chromatin reorganization, transcription, programmed DNA damage, and DSB repair (Chaudhuri and Alt, 2004; Methot and Di Noia, 2017; Yewdell and Chaudhuri, 2017). It is not at all surprising that specific factors could contribute multiple functions within the same or even different steps of the reaction. Indeed, additional Igh locus-specific functions have been described for 53BP1, including enforcement of orientation-specific joining of AID breaks and a structural role in the maintenance of the locus architecture (Dong et al., 2015; Feldman et al., 2017; Rocha et al., 2016). The extent to which these functions contribute to CSR is currently unknown. However, these and our findings suggest that, in addition to preventing resection of AID-induced breaks via Rif1 and the shieldin complex, 53BP1 plays the key role of maintaining the Igh locus in a configuration “primed” for productive CSR events.

No additional role during CSR has been described for Rif1 so far. However, we recently performed a proteomic-based screen to identify Rif1 interactors in primary B lymphocytes undergoing CSR and identified several transcriptional regulators in addition to genome stability factors (Delgado-Benito et al., 2018). This raises the intriguing possibility that Rif1 might contribute to the transcriptional control of CSR. Such a hypothesis is in line with several studies supporting Rif1 role as a transcriptional regulator in yeast and mammals (Dan et al., 2014; Daxinger et al., 2013; Hardy et al., 1992; Kim et al., 2008; Li et al., 2017; Loh et al., 2006; Smith et al., 1999; Tanaka et al., 2016; Wang et al., 2006) and represents an exciting new direction of investigation into the coordinated control of pre- and post-DSB phases of CSR.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **LEAD CONTACT AND MATERIALS AVAILABILITY**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Mice strains
  - Primary cell cultures
  - Cell lines
- **METHOD DETAILS**
  - Protein expression
  - RALS analysis
  - Cell cultures and retroviral infection
  - Generation of 53BP1 oligo mutant expressing CH12 cell lines
  - Western blot analysis and Co-IP assays
  - Flow cytometry
  - Immunofluorescence
  - BrdU assay for DNA end resection
  - Rosa26 DNA end resection assay (Rosa26-ERA)
  - RPA-ChIP
  - Switch Junction Analysis
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND CODE AVAILABILITY**
SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2019.06.035.

ACKNOWLEDGMENTS

We thank all members of the Di Virgilio lab for their feedback and discussion; L. Keller and M. Driesner (Max Delbrück Center [MDC]) for support with cloning, end resection assay, and genotyping; R. Zippen (MDC) for kindly granting access to the lab’s automated foci counting Keyence microscope; the MDC Advanced Light Microscopy (ALM) technology platform for its technical support with the immunofluorescence (IF) assays; the MDC FACS Core Facility and H.P. Rahn for assistance with cell sorting; the MDC Protein Production & Characterization Facility and A. Schütz for providing the MBP control; K. Faebler and J. Schlegel (MDC) for generating and analyzing the RALS data for the MBP control; and R. Pavri (Research Institute of Molecular Pathology [IMP], Vienna) and Y. Doksani (FIRC Institute for Molecular Oncology [IFOM], Milan) for critical reading of the manuscript. This work was supported by European Research Council (ERC) grant 638897 (M.D.V.) and by Helmholtz-Gemeinschaft Zukunftsthema “Immunoology and Inflammation” (grant ZT-0027 to M.D.V. and O.D.). M.D.V. is a Helmholtz Young Investigators Group leader (Helmholtz Association).

AUTHOR CONTRIBUTIONS

Conceptualization, M.D.V.; Investigation, D.S., A.R., M.A., D.T., S.B., T.S., V.D.-B., and V.C.; Formal Analysis, D.S. and M.D.V.; Writing – Original Draft, M.D.V.; Writing – Review & Editing, O.D. and M.D.V.; Visualization, M.D.V.; Supervision, O.D. and M.D.V.; Project Administration, M.D.V.; Funding Acquisition, O.D. and M.D.V.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: February 18, 2019
Revised: May 16, 2019
Accepted: June 7, 2019
Published: August 6, 2019

REFERENCES


Di Virgilio, M., Callen, E., Yamane, A., Zhang, W., Jankovic, M., Gitlin, A.D., Feldhahn, N., Resch, W., Oliveira, T.Y., Chait, B.T., et al. (2013). Rif1 prevents DNA breaks resection and promotes immunoglobulin class switching. Science 339, 711–715.


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat anti-CD180 (RP/14)</td>
<td>BD Biosciences</td>
<td>Cat# 552128, RRID: AB_394343</td>
</tr>
<tr>
<td>Goat anti-IgA-PE</td>
<td>Southern Biotech</td>
<td>Cat# 1040-09</td>
</tr>
<tr>
<td>Mouse anti-CD40 Clone HM40-3</td>
<td>BioLegend</td>
<td>Cat# 102902, RRID:AB_312945</td>
</tr>
<tr>
<td>Rabbit anti-53BP1</td>
<td>Novus Biologicals</td>
<td>Cat# NB100-304, RRID:AB_10003037</td>
</tr>
<tr>
<td>Mouse anti-Flag M2</td>
<td>Sigma-Aldrich</td>
<td>Cat# F3165, RRID: AB_259529</td>
</tr>
<tr>
<td>Mouse anti-Flag M2 (HRP conjugated)</td>
<td>Sigma-Aldrich</td>
<td>Cat# A8592, RRID: AB_439702</td>
</tr>
<tr>
<td>Rabbit anti-Rif1</td>
<td>Di Virgilio et al., 2013</td>
<td>N/A</td>
</tr>
<tr>
<td>Rabbit anti-Tubulin</td>
<td>Abcam</td>
<td>Cat# ab4074 RRID:AB_2288001</td>
</tr>
<tr>
<td>Rat anti-IgG1-APC Clone X56</td>
<td>BD Biosciences</td>
<td>Cat# 550874, RRID: AB_398470</td>
</tr>
<tr>
<td>Rat anti-IgG3-BIOT Clone R40-82</td>
<td>BD Biosciences</td>
<td>Cat# 553401, RRID: AB_394838</td>
</tr>
<tr>
<td>Rat anti-IgG2b-PE Clone RMG2b-1</td>
<td>BioLegend</td>
<td>Cat# 406707, RRID: AB_2563380</td>
</tr>
<tr>
<td>Goat anti-rabbit Alexa546</td>
<td>Invitrogen</td>
<td>Cat# A-11035, RRID: AB_2534093</td>
</tr>
<tr>
<td>Goat anti-mouse Alexa488</td>
<td>Invitrogen</td>
<td>Cat# A-11029, RRID: AB_2534088</td>
</tr>
<tr>
<td>Mouse anti-BrdU APC antibody (Clone Bu20a)</td>
<td>BioLegend</td>
<td>Cat# 339808 RRID:AB_10895898</td>
</tr>
<tr>
<td>Mouse anti-HA probe antibody (F-7)</td>
<td>Santa Cruz</td>
<td>Cat# sc-7392 RRID:AB_627809</td>
</tr>
<tr>
<td>Rabbit anti-HA tag (C29F4)</td>
<td>Cell Signaling</td>
<td>Cat# 3724S RRID:AB_1549585</td>
</tr>
<tr>
<td>Mouse-anti-RPA2 (12F3.3)</td>
<td>Novus Biologicals</td>
<td>Cat# NB100-158 RRID:AB_2180491</td>
</tr>
<tr>
<td>normal mouse IgG</td>
<td>Santa Cruz</td>
<td>Cat# sc-2025 RRID:AB_737182</td>
</tr>
<tr>
<td><strong>Bacterial and Virus Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E.coli BL21 Rosetta 2</td>
<td>Novagen</td>
<td>Cat# 71400</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPMI 1640</td>
<td>Life Technologies</td>
<td>Cat# 21875091</td>
</tr>
<tr>
<td>HEPES</td>
<td>Life Technologies</td>
<td>Cat# 15630056</td>
</tr>
<tr>
<td>Sodium Pyruvate</td>
<td>Life Technologies</td>
<td>Cat# 11360039</td>
</tr>
<tr>
<td>Antibiotic Antimycotic</td>
<td>Life Technologies</td>
<td>Cat# 15240062</td>
</tr>
<tr>
<td>L-Glutamine</td>
<td>Life Technologies</td>
<td>Cat# 25030024</td>
</tr>
<tr>
<td>2-Mercaptoethanol</td>
<td>Life Technologies</td>
<td>Cat# 21985023</td>
</tr>
<tr>
<td>DMEM</td>
<td>Life Technologies</td>
<td>Cat# 41965062</td>
</tr>
<tr>
<td>Penicillin-Streptomycin</td>
<td>Life Technologies</td>
<td>Cat# 15140122</td>
</tr>
<tr>
<td>Express™ medium</td>
<td>Novagen</td>
<td>Cat# 71491</td>
</tr>
<tr>
<td>AEBSF (4-(2-Aminoethyl)benzensulfonylfluorid)</td>
<td>Carl Roth</td>
<td>Cat# A154</td>
</tr>
<tr>
<td>cComplete™ protease inhibitor</td>
<td>Roche</td>
<td>Cat# 11697498001</td>
</tr>
<tr>
<td>Benzonase</td>
<td>Sigma</td>
<td>Cat# E1014-25KU</td>
</tr>
<tr>
<td>Sinapinic acid</td>
<td>Sigma-Aldrich</td>
<td>Cat# ID7927</td>
</tr>
<tr>
<td>Cyano-4-hydroxycinnamic acid</td>
<td>Sigma-Aldrich</td>
<td>Cat# C2020</td>
</tr>
<tr>
<td>Rat anti-CD43 (Ly-48) Microbeads</td>
<td>Miltenyi Biotec</td>
<td>Cat# 130-049-801</td>
</tr>
<tr>
<td>LPS</td>
<td>Sigma-Aldrich</td>
<td>Cat# L2630</td>
</tr>
<tr>
<td>IL-4 (mouse recombinant)</td>
<td>Sigma-Aldrich</td>
<td>Cat# I1020</td>
</tr>
<tr>
<td>BAFF (human recombinant)</td>
<td>PeproTech</td>
<td>Cat# 310-13</td>
</tr>
<tr>
<td>TGFβ-1 (mouse recombinant)</td>
<td>R&amp;D Systems</td>
<td>Cat# 7666-MB-005/CF</td>
</tr>
<tr>
<td>Puromycin dihydrochloride</td>
<td>Sigma-Aldrich</td>
<td>Cat# P8833</td>
</tr>
<tr>
<td>RIPA buffer</td>
<td>Sigma</td>
<td>Cat# R0278</td>
</tr>
<tr>
<td>Complete EDTA-free protease inhibitor cocktail</td>
<td>Roche</td>
<td>Cat# 1187358001</td>
</tr>
</tbody>
</table>

(Continued on next page)
Continued

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>CellTrace Violet</td>
<td>Thermofisher</td>
<td>Cat# C34557</td>
</tr>
<tr>
<td>Paraformaldehyde</td>
<td>Sigma-Aldrich</td>
<td>Cat# P6148</td>
</tr>
<tr>
<td>Hoechst 33258</td>
<td>Thermofisher</td>
<td>Cat# H3569</td>
</tr>
<tr>
<td>Neocarzinostatin (NCS)</td>
<td>Sigma</td>
<td>Cat# N9162</td>
</tr>
<tr>
<td>16% Formaldehyde Methanol-free</td>
<td>Thermo scientific</td>
<td>Cat# 28908</td>
</tr>
<tr>
<td>Dynabeads Protein G</td>
<td>ThermoFisher</td>
<td>Cat# 10004D</td>
</tr>
<tr>
<td>FuGENE® HD Transfection Reagent</td>
<td>Promega</td>
<td>Cat# E2312</td>
</tr>
<tr>
<td>Igepal CA-630</td>
<td>Sigma</td>
<td>Cat# I8896</td>
</tr>
<tr>
<td>Pierce Phosphatase Inhibitor Mini Tablets</td>
<td>ThermoFisher</td>
<td>Cat# A32957</td>
</tr>
<tr>
<td>Phenylmethylsulfonyl fluoride</td>
<td>Sigma-Aldrich</td>
<td>Cat# 10837091001</td>
</tr>
<tr>
<td>Pepstatin A</td>
<td>Merck</td>
<td>Cat# P5318</td>
</tr>
</tbody>
</table>

Critical Commercial Assays

| APC BrdU Flow Kit       | BD Biosciences          | Cat# 552598 |
| Neon Transfection System, 100 μl Kit | Invitrogen             | Cat# MPK10025 |
| Expand Long Template PCR System | Sigma-Aldrich        | Cat# 11681834001 |
| NucleoSpin DNA Purification Kit | Macherey-Nagel      | Cat# 740499 |
| TOPO TA Cloning Kit     | Invitrogen              | Cat# 450641 |
| Luna® Universal One-Step RT-qPCR Kit | NEB            | Cat# E3005S |

Deposited Data

| Original scans and IF images | This paper; Mendeley Data | https://data.mendeley.com/datasets/n7xpbddnf/draft?a=d8838dbd-c9e9-40d5-b467-0150330356a1 |

Experimental Models: Cell Lines

| Murine: CH12 (CH12F3) - WT, parental | Nakamura et al., 1996 | N/A |
| Murine: 53bp1+/− CH12             | Delgado-Benito et al., 2018 | N/A |
| Murine: 53bp1−/− CH12          | This paper | N/A |
| Murine: 53bp1−/− iMEFs       | Bothmer et al., 2011 | N/A |
| Murine: WT iMEFs                | Bothmer et al., 2011 | N/A |
| Human: BOSC23                   | Pear et al., 1993 | N/A |

Experimental Models: Organisms/Strains

| Mouse: 53bp1−/− (and derived splenocytes cultures) | Ward et al., 2003 | N/A |

Oligonucleotides

| 53BP1BRCT-3xHA construct cloning | See Table S2 | N/A |
| 53BP1PRO, 53BP1AMOR, 3xFlag construct cloning | See Table S2 | N/A |
| CRISPR-Cas9 gene targeting        | See Table S2 | N/A |
| RPA ChIP-qPCR                     | See Table S2 | N/A |
| End resection assay               | See Table S2 | N/A |
| Switch junctional analysis         | See Table S2 | N/A |

Recombinant DNA

| Plasmid: pET21b+                 | Novagen                | Cat# 69741 |
| Plasmid: pMAL-C2X                | Addgene                | Cat# #75286|
| Plasmid: pMX-53BP1BRCT-3xFlag    | Bothmer et al., 2011   | N/A |
| Plasmid: pMX-53BP1AMOR-3xFlag    | Ward et al., 2006      | N/A |
| Plasmid: pMX-53BP1Core-3xFlag    | This paper             | N/A |
| Plasmid: pMX-53BP1D125A-3xFlag   | Zgheib et al., 2009    | N/A |
| Plasmid: pMX-53BP1Mmtud-3xFlag   | Botuyan et al., 2006   | N/A |
| Plasmid: pMX-53BP1RA-3xFlag      | Bothmer et al., 2011   | N/A |
| Plasmid: pMX-53BP1Pro-3xFlag     | This paper             | N/A |

(Continued on next page)
LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michela Di Virgilio (michela.divirgilio@mdc-berlin.de).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Sources of mouse models and cell lines used in the study are reported below and in the Key Resources Table.

Mice strains

53bp1<sup>−/−</sup> mice (B6;129-Trp53bp1<sup>tm1Jc</sup>/J) were previously described (Ward et al., 2003). 6 to 20 weeks old animals were used for the study, and age-matched groups were employed within each experiment. Both male and female mice were used for the experiments. Mice were maintained in a specific pathogen-free (SPF) barrier facility under standardized conditions (20±2°C temperature; 55% ± 15% humidity) on a 12 h light/12 h dark cycle. All experiments were performed in compliance with EU Directive 2010/63/EU, and in agreement with protocols approved by Landesamt für Gesundheit und Soziales (LAGeSo, Berlin).

Primary cell cultures

Splenocytes cultures from 53bp1<sup>−/−</sup> mice were grown in RPMI 1640 medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES (Life Technologies), 1 mM Sodium Pyruvate (Life Technologies), 1X Antibiotic Antimycotic (Life Technologies), 2 mM L-Glutamine (Life Technologies), and 1X 2-Mercaptoethanol (Life Technologies) at 37°C and 5% CO2 levels.

Cell lines

The cell lines employed for this study are: CH12 (CH12F3, murine, (Nakamura et al., 1996)), 53bp1<sup>−/−</sup> (Trp53bp1<sup>−/−</sup>) CH12 (murine, (Delgado-Benito et al., 2018)), 53bp1<sup>−/−</sup> CH12 (murine, this paper), WT and 53bp1<sup>−/−</sup> iMEFs (murine, (Boothner et al., 2011)), and BOSC23 (human, (Pear et al., 1993)). CH12 cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES, 1X Antibiotic Antimycotic, 2 mM L-Glutamine, and 1X 2-Mercaptoethanol at 37°C and 5% CO2 levels. iMEFs and BOSC23 cells were cultured in DMEM medium (Life Technologies) supplemented with 10% FBS, 2 mM L-Glutamine, and Penicillin-Streptomycin (Life Technologies) at 37°C and 5% CO2 levels.

METHOD DETAILS

Protein expression

The nucleotide-sequence encoding residues 1233-1288 of human 53BP1 (Uniprot Q12888) was amplified by PCR and cloned into a modified pET21b+ vector (Novagen #69741) encoding N-terminal MBP, followed by a 24 amino acid long linker. Site-directed mutagenesis was used to introduce the indicated mutations. The plasmids were transformed into E.coli BL21 Rosetta 2 (Novagen) and cells were grown at 37°C in Express<sup>TM</sup> medium (Novagen) until an optical density at a wavelength of 600 nm (OD<sub>600</sub>) of 0.9, when the temperature was switched to 18°C for overnight expression. Alternatively, protein was produced in LB medium by inducing protein expression at an OD<sub>600</sub> of 0.4 with 1 mM IPTG and 4 h incubation at 37°C. Cells were harvested by centrifugation and cell pellets stored at −20°C until purification. Thawed cells were resuspended in 20 mM HEPES (or 20 mM Tris-HCl) pH 7.5, 150 mM NaCl, 1 mM...
DTT with AEBSF (4-[(2-Aminophenyl)benzenesulfonfyl]fluoride) and Complete protease inhibitor (Roche) and lysed with a fluidizer (Microfluidics). Cell lysates were centrifuged at 35,000 rpm for 45 min at 4 °C. The filtered supernatant was then incubated with 25 U/ml Benzonase for 25 min at 4 °C to reduce nucleic acid contaminations and subsequently applied to an equilibrated MBP affinity column (GE). The column was washed with 20 column volumes (CV) of resuspension buffer at 4 °C. Protein was eluted with 20 CVs of 20 mM HEPES (or 20 mM Tris-HCl) pH 7.5, 150 mM NaCl, 1 mM DTT, and 40 mM maltose. The eluted protein was concentrated to 20 mg/ml using 10 kDa cutoff Amicon spin filters, followed by size exclusion chromatography on a Superdex S200 in running buffer containing 20 mM HEPES (or 20 mM Tris-HCl) pH 7.5, 150 mM NaCl, 1 mM DTT. Pooled fractions were concentrated to 10 kDa cutoff Amicon spin filters and frozen in small aliquots. Protein size was verified using MALDI-TOF with a 4-point calibration standard and sinapinic acid or z-cyano-4-hydroxycinnamic acid as matrix.

RALS analysis
RALS analysis was performed on an analytical Superdex S200 10/300 column in running buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT, using an ÄKTApurifier and an online Malvern Viscotek RALS system (VE 3580 RI detector and 270 Dual detector). All protein samples were diluted to 2 mg/ml concentration in running buffer. 50 µl of each sample was applied and run at a flow rate of 0.5 ml/min. Data was recorded with UNICORN and OmniSEC 5.00 software and analyzed in OmniSEC 5.00 software. MBP expressed from plasmid pMAL-C2X was used as a control. Molecular weight (MW) of MBP-OD: 49.5 kDa. The clear shift in the elution volume of MBP (MW: 42.5 kDa) and MBP-OD<sup>Δ</sup>Core (MW: 48.6 kDa) in Figure 1B is likely caused by the more extended shape of MBP-OD<sup>Δ</sup>Core.

Cell cultures and retroviral infection
B lymphocytes were isolated from mouse spleens using anti-CD43 MicroBeads (Miltenyi Biotec) and stimulated to undergo class switching with 25 µg/ml LPS (Sigma-Aldrich) and 5 ng/ml of mouse recombinant IL-4 (Sigma-Aldrich) for CSR to IgG1; 25 µg/ml LPS, 10 ng/ml BAFF (PeproTech) and 2 ng/ml TGF<sub>b</sub> for CSR to IgG2b; or 25 µg/ml LPS for CSR to IgG3. Cultures were supplemented with 0.5 µg/ml RP105 (BD) under all stimulation conditions. CH12 cells (Nakamura et al., 1996) were stimulated to undergo CSR to IgA by treatment with 0.5 µg/ml αCD40 (BioLegend), 5 ng/ml TGFβ and 5 ng/ml of mouse recombinant IL-4 for 48 h.

pMX-53BP1 retroviral vectors were generated by cloning the cDNA for human 53BP1<sup>Δ</sup>BRCT (aa 1-1710) into a pMX-based vector with a C-terminal 3xFlag tag. 53BP1<sup>Δ</sup>BRCT backbone was employed as WT and for mutagenesis purposes since its reduced size allows efficient retroviral packaging and infection of B cells, while functionally behaving as the full-length protein in CSR, radial formation, and fusion of deprotected telomeres (Bothmer et al., 2011; Lottersberger et al., 2013). The 53BP1 mutants employed in this study are: 53BP1<sup>Δ</sup>Oligo<sup>a</sup> (Δ1231-1270, (Ward et al., 2000)), 53BP1<sup>Δ</sup>Core<sup>b</sup> (Δ1254-1258, this study), 53BP1<sup>D1256A</sup> (Zghieb et al., 2009), 53BP1<sup>Δ</sup>Misf<sup>c</sup> (D1521R, (Botuyan et al., 2002)), 53BP1<sup>Δ</sup>SA/TA<sup>d</sup> (S6A, S13A, S25A, S29A, S105A, S166A, S176A, S178A, T302A, S437A, S452A, S523A, T543A, S580A, S625A, S674A, T696A, S698A, S784A, S831A, T855A, S892A, S1068A, S1086A, S1104A, S1148A, T1171A, S1219A, (Bothmer et al., 2011)), 53BP1<sup>Δ</sup>Pro<sup>e</sup> (S6A, S13A, S25A, S29A, S105A, S166A, S176A, S178A, T302A, S437A, S452A, S523A, T543A, S580A, S625A, this study), 53BP1<sup>Δ</sup>Mob<sup>f</sup> (S674A, T696A, S698A, S784A, S831A, T855A, S892A, S1068A, S1086A, S1104A, S1148A, T1171A, S1219A, (Lottersberger et al., 2013)), and 53BP1<sup>Δ</sup>L1619A (L1619A, (Fradet-Turcotte et al., 2013)). 53BP1<sup>Δ</sup>Pro was generated by combining the sequence containing the first 15 mutated SQ/TQ to SA/TA sites from 53BP1<sup>WT</sup> and the sequence containing the following 13 mutated SQ/TQ to SA/TA sites from 53BP1<sup>28A</sup> into pMX vector using the same strategy (Ward et al., 2006), 53BP1<sup>Δ</sup>SA/TA<sup>g</sup> (S6A, S13A, S25A, S29A, S105A, S166A, S176A, S178A, T302A, S437A, S452A, S523A, T543A, S580A, S625A, S674A, T696A, S698A, S784A, S831A, T855A, S892A, S1068A, S1086A, S1104A, S1148A, T1171A, S1219A, (Lottersberger et al., 2011)), 53BP1<sup>Δ</sup>Mob<sup>h</sup> (S674A, T696A, S698A, S784A, S831A, T855A, S892A, S1068A, S1086A, S1104A, S1148A, T1171A, S1219A, (Lottersberger et al., 2013)).

Splenocytes infections were performed as it follows. The 293T derivative cell line BOSC23 (Pear et al., 1993) was transfected with pCL-Eco and pMX-53BP1 retroviral vectors using FuGENE® HD Transfection Reagent (Promega) to generate viral particle-containing supernatants. B cells were transduced twice with the viral supernatant, one and two days after isolation, and CSR was assessed 96 h post-activation. To control for any difference in the expression of the transduced constructs within each reconstitution experiment, 53BP1 protein levels were routinely monitored by western blot analysis, as it has been previously described (Bothmer et al., 2011; Callen et al., 2013; Di Virgilio et al., 2013; Fradet-Turcotte et al., 2013). iMEFs were transduced as described for splenocytes above, with the exception that only one round of infection was employed one day after seeding, and 2 µg/ml Puromycin (Sigma-Aldrich) was added to the cultures 24 h after infection.

Generation of 53BP1 oligo mutant expressing CH12 cell lines
CH12 clonal derivatives were generated via electroporation with gRNA pairs and nickase Cas9-based plasmid. Tandem U6 cassettes were cloned into a mutated version of pX458 expressing Cas9<sup>D10A</sup>. Single GFP-positive cells were sorted in 96-well plates and clones were allowed to grow for 12 days before expansion. Clones were validated at the level of genomic scar and protein expression. The
sequences of the gRNAs employed in this study are listed in Table S2. Controls for 53bp1−/− and 53BP1 oligo mutants-expressing clonal derivatives included both WT cultures and clones derived from targeting CH12 with random sequences not present in mouse genome. CH12 cell lines were activated for 48 h with αCD40, IL-4, and TGFβ to induce CSR to IgA.

**Western blot analysis and Co-IP assays**

Western blot analysis of protein levels was performed on whole cell lysates prepared by lysis in RIPA buffer (Sigma) supplemented with Complete EDTA free proteinase inhibitors (Roche).

For co-immunoprecipitation of differentially tagged 53BP1 proteins, BOSC23 cells were co-transfected with equal amounts of pMX-53BP1 WT, 3xHA and pMX-53BP1-3xFlag (WT, ΔOligo, ΔCore, or D1256A) using FuGENE® HD Transfection Reagent. 36 hours post-transfection, cells were irradiated (20 Gy) and left to recover for 1 hour. Cells were lysed in lysis buffer (20 mM Tris HCl, 150 mM NaCl, 0.5% Igepal CA-630 (Sigma), 1.5 mM MgCl2) supplemented with Complete EDTA-free protease inhibitor cocktail, Pepstatin A (Merck), phenylmethylsulfonyl fluoride (PMSF) (Sigma), Pierce Phosphatase Inhibitors (ThermoFisher), and Benzonase (Sigma). Lysates were clarified by 15 min centrifugation at 13,000 rpm at 4°C, and incubated with magnetic beads (DynaBeads Protein G, Thermo Fisher) conjugated with anti-HA antibody (Santa Cruz) for 1 h at 4°C. Proteins were eluted by incubation in NuPAGE LDS sample buffer (Invitrogen) supplemented with 45 mM DTT for 10 min at 72°C.

For 53BP1-Rif1 co-immunoprecipitation analysis, 53bp1−/− splenocytes were activated with 25 μg/ml LPS, 5 ng/ml of mouse re-combinant IL-4, and 0.5 μg/ml RP105, and infected with pMX-53BP1-3xFlag retroviral constructs as described above. At 96 h post-activation, cells were irradiated (20Gy) and left to recover for 1 hour. Cells were harvested, and washed two times with 1x PBS and one time with polyvinylpyrrolidone (PVP) buffer (20 mM HEPES, 1.2% PVP 40, Complete EDTA-free protease inhibitor cocktail, Pierce Phosphatase Inhibitors, 0.5 mM DTT, Pepstatin A, and PMSF). Cells were lysed in lysis buffer (10 mM Tris HCl, 100 mM NaCl, 0.05% Igepal CA-630, 1 mM MgCl2) supplemented with Complete EDTA-free protease inhibitor cocktail, Pierce Phosphatase Inhibitors, Pepstatin A, PMSF, and Benzonase. Lysates were clarified by 15 min centrifugation at 13,000 rpm at 4°C, and incubated with magnetic beads (DynaBeads Protein G, Thermo Fisher) conjugated with anti-Flag M2 antibody (Sigma-Aldrich) for 1 h at 4°C. Proteins were eluted by incubation in NuPAGE LDS sample buffer supplemented with 45 mM DTT for 10 min at 72°C.

The antibodies used for WB analysis are: anti-53BP1 (Novus Biological), anti-Flag M2 (HRP conjugated) (Sigma-Aldrich), anti-Rif1 (Di Virgilio et al., 2013), anti-Tubulin (Abcam), and anti-HA (Cell Signaling).

The indicated MWs of 214 and 190 kDa in the anti-53BP1 blots refer to the endogenous full-length 53BP1 and the retrovirally expressed ΔBRCT proteins, respectively.

**Flow cytometry**

For class switching assays, cell suspensions were stained with fluorochrome-conjugated anti-IgG1, anti-IgG3 (BD-Biosciences), anti-IgG2b (BioLegend), or anti-IgA (Southern Biotech). Samples were acquired on an LSRFortessa cell analyzer (BD-Biosciences). For cell proliferation analysis by cell tracking dye dilution, primary B cells were pulsed with 5 μM CellTrace Violet (Thermofisher) for 20 min at 37°C.

**Immunofluorescence**

iMEFs were grown on coverslips overnight. Cells were irradiated (10 Gy IR) and allowed to recover for 2 h. Upon fixation with 4% paraformaldehyde (Sigma-Aldrich) and permeabilization with 0.5% Triton X-100, cells were stained with mouse anti-Flag M2 (Sigma-Aldrich), and rabbit anti-Rif1 serum (Di Virgilio et al., 2013) antibodies as primary antibodies, and with goat anti-rabbit Alexa546 and goat anti-mouse Alexa488 (Invitrogen) as secondary antibodies, alongside permeable nuclear dye (Hoechst dye 33342, ThermoFisher). Images were acquired using inverted LSM700 laser scanning confocal microscope (Zeiss) for the representative images in Figures S2B and S2D, and with inverted fluorescence phase contrast microscope Keyence BZ-X800E (Keyence) for the automated foci quantification in Figures 1F, 1G, 2B, and 2C.

**BrdU assay for DNA end resection**

The BrdU assay for DNA end resection was performed as previously described (Tkác et al., 2016). Briefly, iMEFs were incubated with 30 μM BrdU for 24 h, followed by treatment with 200 ng/ml Neocarzinostatin (NCS) for 3 h (+NCS samples) or mock-treated (-NCS samples). Cells were trypsinized, washed with PBS, and fixed with 75% ethanol in PBS for 16 h at −20°C. Cells were washed with 0.1% Tween 20 in PBS following fixation and each subsequent incubation. Each sample was split into 2 aliquots, one of which was denatured using 2 N HCl for 45 min at 22°C in order to measure total BrdU incorporation. Blocking was performed in 5% fetal bovine serum (FBS) in PBS for 1 h at 22°C. BrdU exposed on single-stranded DNA (ssDNA) stretches as a consequence of DNA end resection was detected under native conditions by incubation with APC-conjugated anti-BrdU antibody (BioLegend) in PBS supplemented with 5% FBS for 1 h at 22°C. BrdU fluorescence intensity was acquired using the BD LSRFortessa flow cytometer (BD Biosciences). Resection levels in Figures 1J and 2E were expressed as the mean BrdU intensity of native NCS-treated cells normalized to the mean BrdU intensity value of the same cells under denatured conditions.
Rosa26 DNA end resection assay (Rosa26-ERA)

The end resection assay was performed as previously described (Delgado-Benito et al., 2018). Single guide RNAs targeting two sequences 2276 bp apart within the ROSA26 locus (gDSB-1 and gDSB-2) were cloned independently into pX458 plasmid (gDSB-1/2). CH12 cells were electroporated with a 1:1 mix of gDSB-1 and gDSB-2 constructs using the Neon Transfection System (Thermo Fisher Scientific). 24h later, GFP-positive cells were sorted and pellets were frozen. Genomic DNA was extracted according to standard protocols and individual repair junctions were amplified using nested PCR reactions. PCR products were extracted from agarose gel and sequenced. Single guide RNAs and primers used for the end resection assay are listed in Table S2.

RPA-ChIP

ChIP-qPCR for RPA was performed as it follows. 20 million cells were counted and stimulated for 30 h with 0.5 μg/ml αCD40, 5 ng/ml TGFβ, and 5 ng/ml of mouse recombinant IL-4. Cells were fixed with 1% Formaldehyde (Thermo Scientific) at 37°C for 10 min followed by addition of 1/20 volume of 2.5 M glycine (dissolved in PBS pH 7.4). Fixed cells were washed two times with ice cold PBS, centrifuged and aliquoted. Cells were resuspended in 800 μL of RIPA buffer supplemented with Complete EDTA free proteinase inhibitor and sonication was performed with a Covaris S220 Focused Ultrasonicator (peak value 105, duty factor 5, cycle/burst 200 for 20 minutes). Each ChIP was performed using 50-60 μg of chromatin. Chromatin fragments were pre-cleaned by incubation with Dynabeads Protein G (Thermofisher) with rotation at 4°C for 1 h, and immunoprecipitated with antibody-bound Dynabeads. 10 μg antibodies specific for RPA2 (Novus Biologicals) or normal mouse IgG (Santa Cruz) were used for each sample. DNA was amplified using Luna® Universal One-Step RT-qPCR Kit (NEB) on a StepOnePlus qPCR machine (Thermofisher). Primers used for RPA-ChIP analysis (Wiedemann et al., 2016) are listed in Table S2.

Switch Junction Analysis

For Sm-Sa junctional analysis in CH12, cells were stimulated for 48 h with 0.5 μg/ml αCD40, 5 ng/ml TGFβ and 5 ng/ml of mouse recombinant IL-4, and sorted for IgA+ cells. Genomic DNA was extracted from the sorted population, and Sm-Sa junctions were amplified by Expand long template PCR system (Sigma Aldrich). PCR conditions were: 38 cycles of denaturation 94°C for 1500, annealing 60°C for 300, and elongation 68°C for 300 (plus 300 at each following cycle). PCR products were run on agarose gels, and fragments corresponding to 350-1000 bp were extracted with NucleoSpin DNA Purification Kit (Macherey-Nagel), cloned using TOPO-TA cloning kit (Invitrogen), and sequenced using M13 forward and reverse universal primers. Primers used for switch junction analysis (Lee-Theilen et al., 2011) are listed in Table S2.

QUANTIFICATION AND STATISTICAL ANALYSIS

The statistical significance of differences between groups/datasets was determined by the Mann–Whitney U test for all data presented in this study. Error bars in Figures 1D, 1J, 2E, 3D–3F, 4A, and S3C represent SD. Statistical details of experiments can also be found in the figure legends. Western blots were quantified using ImageJ image processing program (NIH). For quantification of oligomutant versus WT 53BP1-3xFlag proteins in anti-HA immunoprecipitates in Figure 1C, the signal associated with 53BP1-3xFlag proteins was normalized against the levels of 53BP1WT-3xHA in each corresponding pull-down. For quantification of 53BP1 protein levels in the western blot analyses in Figures 3A–3C, and repeats, the signal associated to 53BP1 was normalized with that of a aspecific reference band present in all lanes. IR-induced foci quantification in Figures 1F, 1G, and 2B, and 2C was performed using the BZ-H4A/Advanced Analysis Software, BZ-H4C/Hybrid Cell Count and BZ-H4CM/Macro Cell Count analysis applications (Keyence).

DATA AND CODE AVAILABILITY

Original imaging and western blot data used to generate any of the figure panels have been deposited at Mendeley: https://data.mendeley.com/datasets/n7jxbpddnf/draft?a=d8838dbd-c9e9-40d5-b467-0150330356a1